Skip to main content
PMC home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2008;317:155–183. doi: 10.1007/978-3-540-72146-8_6

Exploring the Native Human Antibody Repertoire to Create Antiviral Therapeutics

Scott K Dessain 10, S P Adekar 10, J D Berry 11
Editor: Scott K Dessain1
PMCID: PMC7121815  PMID: 17990793

Abstract

Native human antibodies are defined as those that arise naturally as the result of the functioning of an intact human immune system. The utility of native antibodies for the treatment of human viral diseases has been established through experience with hyperimmune human globulins. Native antibodies, as a class, differ in some respects from those obtained by recombinant library methods (phage or transgenic mouse) and possess distinct properties that may make them ideal therapeutics for human viral diseases. Methods for cloning native human antibodies have been beset by technical problems, yet many antibodies specific for viral antigens have been cloned. In the present review, we discuss native human antibodies and ongoing improvements in cloning methods that should facilitate the creation of novel, potent antiviral therapeutics obtained from the native human antibody repertoire.

Keywords: Respiratory Syncytial Virus, West Nile Virus, Severe Acute Respiratory Syndrome, Rabies Virus, Human Monoclonal Antibody

Contributor Information

Scott K. Dessain, Email: scott.dessain@jefferson.edu.

Scott K. Dessain, Email: scott.dessain@jefferson.edu.

References

  1. Amersdorfer P, Wong C, Smith T, Chen S, Deshpande S, Sheridan R, Marks JD. Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries. Vaccine. 2002;20:1640–1648. doi: 10.1016/S0264-410X(01)00482-0. [DOI] [PubMed] [Google Scholar]
  2. Ames RS, Tornetta MA, McMillan LJ, Kaiser KF, Holmes SD, Appelbaum E, Cusimano DM, Theisen TW, Gross MS, Jones CS, et al. Neutralizing murine monoclonal antibodies to human IL-5 isolated from hybridomas and a filamentous phage Fab display library. J Immunol. 1995;154:6355–6364. [PubMed] [Google Scholar]
  3. Andris JS, Ehrlich PH, Ostberg L, Capra JD. Probing the human antibody repertoire to exogenous antigens. Characterization of the H and L chain V region gene segments from anti-hepatitis B virus antibodies. J Immunol. 1992;149:4053–4059. [PubMed] [Google Scholar]
  4. Arakelov S, Gorny MK, Williams C, Riggin CH, Brady F, Collett MS, Zolla-Pazner S. Generation of neutralizing anti-B19 parvovirus human monoclonal antibodies from patients infected with human immunodeficiency virus. J Infect Dis. 1993;168:580–585. doi: 10.1093/infdis/168.3.580. [DOI] [PubMed] [Google Scholar]
  5. Arinbjarnarson S, Valdimarsson H. Generation of heterohybridomas secreting human immunoglobulins; pokeweed mitogen prestimulation is highly effective but phytohemagglutinin drives most B cells into apoptosis. J Immunol Methods. 2002;259:139–148. doi: 10.1016/S0022-1759(01)00504-X. [DOI] [PubMed] [Google Scholar]
  6. Aujard Y, Fauroux B. Risk factors for severe respiratory syncytial virus infection in infants. Respir Med. 2002;96(B):S9–S14. [PubMed] [Google Scholar]
  7. Babcook JS, Leslie KB, Olsen OA, Salmon RA, Schrader JW. A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities. Proc Natl Acad Sci U S A. 1996;93:7843–7848. doi: 10.1073/pnas.93.15.7843. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Bailey SM, Murnane JP. Telomeres, chromosome instability and cancer. Nucleic Acids Res. 2006;34:2408–2417. doi: 10.1093/nar/gkl303. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Bakker AB, Marissen WE, Kramer RA, Rice AB, Weldon WC, Niezgoda M, Hanlon CA, Thijsse S, Backus HH, de Kruif J, Dietzschold B, Rupprecht CE, Goudsmit J. Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants. J Virol. 2005;79:9062–9068. doi: 10.1128/JVI.79.14.9062-9068.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Banchereau J, Rousset F. Growing human B lymphocytes in the CD40 system. Nature. 1991;353:678–679. doi: 10.1038/353678a0. [DOI] [PubMed] [Google Scholar]
  11. Barbas CF., 3rd Recent advances in phage display. Curr Opin Biotechnol. 1993;4:526–530. doi: 10.1016/0958-1669(93)90072-5. [DOI] [PubMed] [Google Scholar]
  12. Bazin R, Lemieux R. Increased proportion of B cell hybridomas secreting monoclonal antibodies of desired specificity in cultures containing macrophage-derived hybridoma growth factor (IL-6) J Immunol Methods. 1989;116:245–249. doi: 10.1016/0022-1759(89)90210-X. [DOI] [PubMed] [Google Scholar]
  13. Biron KK. Antiviral drugs for cytomegalovirus diseases. Antiviral Res. 2006;71:154–163. doi: 10.1016/j.antiviral.2006.05.002. [DOI] [PubMed] [Google Scholar]
  14. Boder ET, Wittrup KD. Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol. 1997;15:553–557. doi: 10.1038/nbt0697-553. [DOI] [PubMed] [Google Scholar]
  15. Boeckh M, Bowden RA, Storer B, Chao NJ, Spielberger R, Tierney DK, Gallez-Hawkins G, Cunningham T, Blume KG, Levitt D, Zaia JA. Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2001;7:343–351. doi: 10.1016/S1083-8791(01)80005-7. [DOI] [PubMed] [Google Scholar]
  16. Boeckh M, Leisenring W, Riddell SR, Bowden RA, Huang ML, Myerson D, Stevens-Ayers T, Flowers ME, Cunningham T, Corey L. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood. 2003;101:407–414. doi: 10.1182/blood-2002-03-0993. [DOI] [PubMed] [Google Scholar]
  17. Borrebaeck CA, Danielsson L, Moller SA. Human monoclonal antibodies produced from L-leucine methyl ester-treated and in vitro immunized peripheral blood lymphocytes. Biochem Biophys Res Commun. 1987;148:941–946. doi: 10.1016/S0006-291X(87)80223-1. [DOI] [PubMed] [Google Scholar]
  18. Borrebaeck CA, Danielsson L, Moller SA. Human monoclonal antibodies produced by primary in vitro immunization of peripheral blood lymphocytes. Proc Natl Acad Sci USA. 1988;85:3995–3999. doi: 10.1073/pnas.85.11.3995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Borucki MJ, Spritzler J, Asmuth DM, Gnann J, Hirsch MS, Nokta M, Aweeka F, Nadler PI, Sattler F, Alston B, Nevin TT, Owens S, Waterman K, Hubbard L, Caliendo A, Pollard RB. A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with cytomegalovirus retinitis. Antiviral Res. 2004;64:103–111. doi: 10.1016/j.antiviral.2004.06.012. [DOI] [PubMed] [Google Scholar]
  20. Bradbury AR, Marks JD. Antibodies from phage antibody libraries. J Immunol Methods. 2004;290:29–49. doi: 10.1016/j.jim.2004.04.007. [DOI] [PubMed] [Google Scholar]
  21. Brezinschek HP, Brezinschek RI, Lipsky PE. Analysis of the heavy chain repertoire of human peripheral B cells using single-cell polymerase chain reaction. J Immunol. 1995;155:190–202. [PubMed] [Google Scholar]
  22. Broliden K, Tolfvenstam T, Norbeck O. Clinical aspects of parvovirus B19 infection. J Intern Med. 2006;260:285–304. doi: 10.1111/j.1365-2796.2006.01697.x. [DOI] [PubMed] [Google Scholar]
  23. Bron D, Delforge A, Lagneaux L, De Martynoff G, Bosmans E, Van der Auwera P, Snoeck R, Burny A, Stryckmans P. Production of human monoclonal IgG antibodies reacting with cytomegalovirus (CMV) J Immunol Methods. 1990;130:209–216. doi: 10.1016/0022-1759(90)90050-6. [DOI] [PubMed] [Google Scholar]
  24. Brown NA, Miller G. Immunoglobulin expression by human B lymphocytes clonally transformed by Epstein Barr virus. J Immunol. 1982;128:24–29. [PubMed] [Google Scholar]
  25. Butler JL, Lane HC, Fauci AS. Delineation of optimal conditions for producing mouse-human heterohybridomas from human peripheral blood B cells of immunized subjects. J Immunol. 1983;130:165–168. [PubMed] [Google Scholar]
  26. Carman WF, Trautwein C, van Deursen FJ, Colman K, Dornan E, McIntyre G, Waters J, Kliem V, Muller R, Thomas HC, Manns MP. Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis. Hepatology. 1996;24:489–493. doi: 10.1002/hep.510240304. [DOI] [PubMed] [Google Scholar]
  27. Carroll WL, Thielemans K, Dilley J, Levy R. Mouse x human heterohybridomas as fusion partners with human B cell tumors. J Immunol Methods. 1986;89:61–72. doi: 10.1016/0022-1759(86)90032-3. [DOI] [PubMed] [Google Scholar]
  28. Casadevall A, Pirofski LA. The potential of antibody-mediated immunity in the defence against biological weapons. Expert Opin Biol Ther. 2005;5:1359–1372. doi: 10.1517/14712598.5.10.1359. [DOI] [PubMed] [Google Scholar]
  29. Casadevall A, Dadachova E, Pirofski LA. Passive antibody therapy for infectious diseases. Nat Rev Microbiol. 2004;2:695–703. doi: 10.1038/nrmicro974. [DOI] [PubMed] [Google Scholar]
  30. Casali P, Inghirami G, Nakamura M, Davies TF, Notkins AL. Human monoclonals from antigen-specific selection of B lymphocytes and transformation by EBV. Science. 1986;234:476–479. doi: 10.1126/science.3020687. [DOI] [PubMed] [Google Scholar]
  31. CDC Postexposure prophylaxis of hepatitis B. Morb Mortal Wkly Rep. 1984;33:285–290. [PubMed] [Google Scholar]
  32. CDC Recommendations for protection against viral hepatitis. Morb Mortal Wkly Rep. 1985;34:313–324. [PubMed] [Google Scholar]
  33. CDC Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention. MMWR Recomm Rep. 1996;45:1–36. [PubMed] [Google Scholar]
  34. CDC MSL-109 adjuvant therapy for cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: the Monoclonal Antibody Cytomegalovirus Retinitis Trial. The Studies of Ocular Complications of AIDS Research Group. AIDS Clinical Trials Group. Arch Ophthalmol. 1997;115:1528–1536. [PubMed] [Google Scholar]
  35. CDC Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group. Pediatrics. 1997;99:93–99. doi: 10.1542/peds.99.1.93. [DOI] [PubMed] [Google Scholar]
  36. CDC Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics. 1998;102:531–537. doi: 10.1542/peds.102.3.531. [DOI] [PubMed] [Google Scholar]
  37. CDC A new product (VariZIG) for postexposure prophylaxis of varicella available under an investigational new drug application expanded access protocol. MMWR Morb Mortal Wkly Rep. 2006;55:209–210. [PubMed] [Google Scholar]
  38. Cerino A, Boender P, La Monica N, Rosa C, Habets W, Mondelli MU. A human monoclonal antibody specific for the N terminus of the hepatitis C virus nucleocapsid protein. J Immunol. 1993;151:7005–7015. [PubMed] [Google Scholar]
  39. Champion JM, Kean RB, Rupprecht CE, Notkins AL, Koprowski H, Dietzschold B, Hooper DC. The development of monoclonal human rabies virus-neutralizing antibodies as a substitute for pooled human immune globulin in the prophylactic treatment of rabies virus exposure. J Immunol Methods. 2000;235:81–90. doi: 10.1016/S0022-1759(99)00223-9. [DOI] [PubMed] [Google Scholar]
  40. Chiorazzi N, Wasserman RL, Kunkel HG. Use of Epstein-Barr virus-transformed B cell lines for the generation of immunoglobulin-producing human B cell hybridomas. J Exp Med. 1982;156:930–935. doi: 10.1084/jem.156.3.930. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Cieplinski W, Reardon P, Testa MA. Non-random human chromosome distribution in human-mouse myeloma somatic cell hybrids. Cytogenet Cell Genet. 1983;35:93–99. doi: 10.1159/000131848. [DOI] [PubMed] [Google Scholar]
  42. Cole SP, Campling BG, Louwman IH, Kozbor D, Roder JC. A strategy for the production of human monoclonal antibodies reactive with lung tumor cell lines. Cancer Res. 1984;44:2750–2753. [PubMed] [Google Scholar]
  43. Colucci G, Kohtz DS, Waksal SD. Preparation and characterization of human monoclonal antibodies directed against the hepatitis B virus surface antigen. Liver. 1986;6:145–152. doi: 10.1111/j.1600-0676.1986.tb00281.x. [DOI] [PubMed] [Google Scholar]
  44. Cote RJ, Morrissey DM, Houghton AN, Beattie EJ, Jr, Oettgen HF, Old LJ. Generation of human monoclonal antibodies reactive with cellular antigens. Proc Natl Acad Sci USA. 1983;80:2026–2030. doi: 10.1073/pnas.80.7.2026. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Counter CM, Avilion AA, LeFeuvre CE, Stewart NG, Greider CW, Harley CB, Bacchetti S. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J. 1992;11:1921–1929. doi: 10.1002/j.1460-2075.1992.tb05245.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Croce CM, Linnenbach A, Hall W, Steplewski Z, Koprowski H. Production of human hybridomas secreting antibodies to measles virus. Nature. 1980;288:488–489. doi: 10.1038/288488a0. [DOI] [PubMed] [Google Scholar]
  47. Darveau A, Chevrier MC, Neron S, Delage R, Lemieux R. Efficient preparation of human monoclonal antibody-secreting heterohybridomas using peripheral B lymphocytes cultured in the CD40 system. J Immunol Methods. 1993;159:139–143. doi: 10.1016/0022-1759(93)90151-V. [DOI] [PubMed] [Google Scholar]
  48. Daugherty PS, Olsen MJ, Iverson BL, Georgiou G. Development of an optimized expression system for the screening of antibody libraries displayed on the Escherichia coli surface. Protein Eng. 1999;12:613–621. doi: 10.1093/protein/12.7.613. [DOI] [PubMed] [Google Scholar]
  49. de Kruif J, Bakker AB, Marissen WE, Kramer RA, Throsby M, Rupprecht CE, Goudsmit J. A human monoclonal antibody cocktail as a novel component of rabies postexposure prophylaxis. Annu Rev Med. 2006;58:359–368. doi: 10.1146/annurev.med.58.061705.145053. [DOI] [PubMed] [Google Scholar]
  50. Desgranges C, Paire J, Pichoud C, Souche S, Frommel D, Trepo C. High affinity human monoclonal antibodies directed against hepatitis B surface antigen. J Virol Methods. 1987;16:281–292. doi: 10.1016/0166-0934(87)90013-9. [DOI] [PubMed] [Google Scholar]
  51. Dessain SK, Adekar SP, Stevens JB, Carpenter KA, Skorski ML, Barnoski BL, Goldsby RA, Weinberg RA. High efficiency creation of human monoclonal antibody-producing hybridomas. J Immunol Methods. 2004;291:109–122. doi: 10.1016/j.jim.2004.05.005. [DOI] [PubMed] [Google Scholar]
  52. DeVincenzo JP, Hirsch RL, Fuentes RJ, Top FH., Jr Respiratory syncytial virus immune globulin treatment of lower respiratory tract infection in pediatric patients undergoing bone marrow transplantation—a compassionate use experience. Bone Marrow Transplant. 2000;25:161–165. doi: 10.1038/sj.bmt.1702118. [DOI] [PubMed] [Google Scholar]
  53. Di Paolo D, Tisone G, Piccolo P, Lenci I, Zazza S, Angelico M. Low-dose hepatitis B immunoglobulin given “on demand” in combination with lamivudine: a highly cost-effective approach to prevent recurrent hepatitis B virus infection in the long-term follow-up after liver transplantation. Transplantation. 2004;77:1203–1208. doi: 10.1097/01.TP.0000118904.63669.EB. [DOI] [PubMed] [Google Scholar]
  54. Dietzschold B, Gore M, Casali P, Ueki Y, Rupprecht CE, Notkins AL, Koprowski H. Biological characterization of human monoclonal antibodies to rabies virus. J Virol. 1990;64:3087–3090. doi: 10.1128/jvi.64.6.3087-3090.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Dorfman N, Dietzschold B, Kajiyama W, Fu ZF, Koprowski H, Notkins AL. Development of human monoclonal antibodies to rabies. Hybridoma. 1994;13:397–402. doi: 10.1089/hyb.1994.13.397. [DOI] [PubMed] [Google Scholar]
  56. Drobyski WR, Gottlieb M, Carrigan D, Ostberg L, Grebenau M, Schran H, Magid P, Ehrlich P, Nadler PI, Ash RC. Phase I study of safety and pharmacokinetics of a human anticytomegalovirus monoclonal antibody in allogeneic bone marrow transplant recipients. Transplantation. 1991;51:1190–1196. doi: 10.1097/00007890-199106000-00009. [DOI] [PubMed] [Google Scholar]
  57. Ebeling SB, Bos HM, Slater R, Overkamp WJ, Cuthbert AP, Newbold RF, Zdzienicka MZ, Aarden LA. Human chromosome 21 determines growth factor dependence in human/mouse B-cell hybridomas. Cancer Res. 1998;58:2863–2868. [PubMed] [Google Scholar]
  58. Ehrlich PH, Moustafa ZA, Justice JC, Harfeldt KE, Kelley RL, Ostberg L. Characterization of human monoclonal antibodies directed against hepatitis B surface antigen. Hum Antibodies Hybridomas. 1992;3:2–7. [PubMed] [Google Scholar]
  59. Eid AJ, Brown RA, Patel R, Razonable RR. Parvovirus B19 infection after transplantation: a review of 98 cases. Clin Infect Dis. 2006;43:40–48. doi: 10.1086/504812. [DOI] [PubMed] [Google Scholar]
  60. Emanuel D, Gold J, Colacino J, Lopez C, Hammerling U. A human monoclonal antibody to cytomegalovirus (CMV) J Immunol. 1984;133:2202–2205. [PubMed] [Google Scholar]
  61. Enssle K, Kurrle R, Kohler R, Muller H, Kanzy EJ, Hilfenhaus J, Seiler FR. A rabies-specific human monoclonal antibody that protects mice against lethal rabies. Hybridoma. 1991;10:547–556. doi: 10.1089/hyb.1991.10.547. [DOI] [PubMed] [Google Scholar]
  62. Ephrussi B, Weiss MC. Hybrid somatic cells. Sci Am. 1969;220:26–35. doi: 10.1038/scientificamerican0469-26. [DOI] [PubMed] [Google Scholar]
  63. Ergaz Z, Ornoy A. Parvovirus B19 in pregnancy. Reprod Toxicol. 2006;21:421–435. doi: 10.1016/j.reprotox.2005.01.006. [DOI] [PubMed] [Google Scholar]
  64. Faller G, Vollmers HP, Weiglein I, Marx A, Zink C, Pfaff M, Muller-Hermelink HK. HAB-1, a new heteromyeloma for continuous production of human monoclonal antibodies. Br J Cancer. 1990;62:595–598. doi: 10.1038/bjc.1990.336. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005;352:1749–1759. doi: 10.1056/NEJMoa043951. [DOI] [PubMed] [Google Scholar]
  66. Ferretti G, Merli M, Ginanni Corradini S, Callejon V, Tanzilli P, Masini A, Ferretti S, Iappelli M, Rossi M, Rivanera D, Lilli D, Mancini C, Attili A, Berloco P. Low-dose intramuscular hepatitis B immune globulin and lamivudine for long-term prophylaxis of hepatitis B recurrence after liver transplantation. Transplant Proc. 2004;36:535–538. doi: 10.1016/j.transproceed.2004.02.025. [DOI] [PubMed] [Google Scholar]
  67. Fiore AE, Wasley A, Bell BP. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Recomm Rep. 2006;55:1–23. [PubMed] [Google Scholar]
  68. Foung S, Perkins S, Kafadar K, Gessner P, Zimmermann U. Development of microfusion techniques to generate human hybridomas. J Immunol Methods. 1990;134:35–42. doi: 10.1016/0022-1759(90)90109-9. [DOI] [PubMed] [Google Scholar]
  69. Foung SK, Perkins S, Raubitschek A, Larrick J, Lizak G, Fishwild D, Engleman EG, Grumet FC. Rescue of human monoclonal antibody production from an EBV-transformed B cell line by fusion to a human-mouse hybridoma. J Immunol Methods. 1984;70:83–90. doi: 10.1016/0022-1759(84)90392-2. [DOI] [PubMed] [Google Scholar]
  70. Foung SK, Perkins S, Koropchak C, Fishwild DM, Wittek AE, Engleman EG, Grumet FC, Arvin AM. Human monoclonal antibodies neutralizing varicella-zoster virus. J Infect Dis. 1985;152:280–285. doi: 10.1093/infdis/152.2.280. [DOI] [PubMed] [Google Scholar]
  71. Foung SK, Perkins S, Bradshaw P, Rowe J, Rabin LB, Reyes GR, Lennette ET. Human monoclonal antibodies to human cytomegalovirus. J Infect Dis. 1989;159:436–443. doi: 10.1093/infdis/159.3.436. [DOI] [PubMed] [Google Scholar]
  72. Fowler KB, Stagno S, Pass RF, Britt WJ, Boll TJ, Alford CA. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med. 1992;326:663–667. doi: 10.1056/NEJM199203053261003. [DOI] [PubMed] [Google Scholar]
  73. Gandhi MK, Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis. 2004;4:725–738. doi: 10.1016/S1473-3099(04)01202-2. [DOI] [PubMed] [Google Scholar]
  74. Gebauer W, Lindl T. Construction of human monoclonal antibodies against rabies NS-protein antigen by Epstein-Barr virus transformation. Arzneimittelforschung. 1990;40:718–722. [PubMed] [Google Scholar]
  75. Geetha D, Zachary JB, Baldado HM, Kronz JD, Kraus ES. Pure red cell aplasia caused by Parvovirus B19 infection in solid organ transplant recipients: a case report and review of literature. Clin Transplant. 2000;14:586–591. doi: 10.1034/j.1399-0012.2000.140612.x. [DOI] [PubMed] [Google Scholar]
  76. Ghany MG, Ayola B, Villamil FG, Gish RG, Rojter S, Vierling JM, Lok AS. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology. 1998;27:213–222. doi: 10.1002/hep.510270133. [DOI] [PubMed] [Google Scholar]
  77. Ghosh S, Champlin RE, Englund J, Giralt SA, Rolston K, Raad I, Jacobson K, Neumann J, Ippoliti C, Mallik S, Whimbey E. Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin. Bone Marrow Transplant. 2000;25:751–755. doi: 10.1038/sj.bmt.1702228. [DOI] [PubMed] [Google Scholar]
  78. Gigler A, Dorsch S, Hemauer A, Williams C, Kim S, Young NS, Zolla-Pazner S, Wolf H, Gorny MK, Modrow S. Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins. J Virol. 1999;73:1974–1979. doi: 10.1128/jvi.73.3.1974-1979.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  79. Gish RG, McCashland T. Hepatitis B in liver transplant recipients. Liver Transpl. 2006;12:S54–S64. doi: 10.1002/lt.20950. [DOI] [PubMed] [Google Scholar]
  80. Goldsmith JC, Eller N, Mikolajczyk M, Manischewitz J, Golding H, Scott DE. Intravenous immunoglobulin products contain neutralizing antibodies to vaccinia. Vox Sang. 2004;86:125–129. doi: 10.1111/j.0042-9007.2004.00397.x. [DOI] [PubMed] [Google Scholar]
  81. Gray F, Kenney JS, Dunne JF. Secretion capture and report web: use of affinity derivatized agarose microdroplets for the selection of hybridoma cells. J Immunol Methods. 1995;182:155–163. doi: 10.1016/0022-1759(94)00319-R. [DOI] [PubMed] [Google Scholar]
  82. Griffiths AD, Williams SC, Hartley O, Tomlinson IM, Waterhouse P, Crosby WL, Kontermann RE, Jones PT, Low NM, Allison TJ, et al. Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J. 1994;13:3245–3260. doi: 10.1002/j.1460-2075.1994.tb06626.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  83. Grunow R, Jahn S, Porstmann T, Kiessig SS, Steinkellner H, Steindl F, Mattanovich D, Gurtler L, Deinhardt F, Katinger H, et al. The high efficiency, human B cell immortalizing heteromyeloma CB-F7. Production of human monoclonal antibodies to human immunodeficiency virus. J Immunol Methods. 1988;106:257–265. doi: 10.1016/0022-1759(88)90206-2. [DOI] [PubMed] [Google Scholar]
  84. Gustafsson B, Jondal M, Sundqvist VA. SPAM-8, a mouse-human heteromyeloma fusion partner in the production of human monoclonal antibodies. Establishment of a human monoclonal antibody against cytomegalovirus. Hum Antibodies Hybridomas. 1991;2:26–32. [PubMed] [Google Scholar]
  85. Hadlock KG, Rowe J, Perkins S, Bradshaw P, Song GY, Cheng C, Yang J, Gascon R, Halmos J, Rehman SM, McGrath MS, Foung SK. Neutralizing human monoclonal antibodies to conformational epitopes of human T-cell lymphotropic virus type 1 and 2 gp46. J Virol. 1997;71:5828–5840. doi: 10.1128/jvi.71.8.5828-5840.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  86. Hadlock KG, Lanford RE, Perkins S, Rowe J, Yang Q, Levy S, Pileri P, Abrignani S, Foung SK. Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes. J Virol. 2000;74:10407–10416. doi: 10.1128/JVI.74.22.10407-10416.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  87. Hangartner L, Zinkernagel RM, Hengartner H. Antiviral antibody responses: the two extremes of a wide spectrum. Nat Rev Immunol. 2006;6:231–243. doi: 10.1038/nri1783. [DOI] [PubMed] [Google Scholar]
  88. Harris JF, Koropatnick J, Pearson J. Spontaneous and radiation-induced genetic instability of heteromyeloma hybridoma cells. Mol Biol Med. 1990;7:485–493. [PubMed] [Google Scholar]
  89. Harris JF, Hawley RG, Hawley TS, Crawford-Sharpe GC. Increased frequency of both total and specific monoclonal antibody producing hybridomas using a fusion partner that constitutively expresses recombinant IL-6. J Immunol Methods. 1992;148:199–207. doi: 10.1016/0022-1759(92)90173-Q. [DOI] [PubMed] [Google Scholar]
  90. Hartmann G, Krieg AM. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J Immunol. 2000;164:944–953. doi: 10.4049/jimmunol.164.2.944. [DOI] [PubMed] [Google Scholar]
  91. Heijtink R, Paulij W, van Bergen P, van Roosmalen M, Rohm D, Eichentopf B, Muchmore E, de Man R, Osterhaus A. In vivo activity of a mixture of two human monoclonal antibodies (anti-HBs) in a chronic hepatitis B virus carrier chimpanzee. J Gen Virol. 1999;80:1529–1535. doi: 10.1099/0022-1317-80-6-1529. [DOI] [PubMed] [Google Scholar]
  92. Heijtink RA, Kruining J, Weber YA, de Man RA, Schalm SW. Anti-hepatitis B virus activity of a mixture of two monoclonal antibodies in an “inhibition in solution” assay. Hepatology. 1995;22:1078–1083. doi: 10.1002/hep.1840220410. [DOI] [PubMed] [Google Scholar]
  93. Henderson DA, Inglesby TV, Bartlett JG, Ascher MS, Eitzen E, Jahrling PB, Hauer J, Layton M, McDade J, Osterholm MT, O’Toole T, Parker G, Perl T, Russell PK, Tonat K. Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA. 1999;281:2127–2137. doi: 10.1001/jama.281.22.2127. [DOI] [PubMed] [Google Scholar]
  94. Hirano T. Interleukin 6 and its receptor: ten years later. Int Rev Immunol. 1998;16:249–284. doi: 10.3109/08830189809042997. [DOI] [PubMed] [Google Scholar]
  95. Hoffmann P, Jimenez-Diaz M, Weckesser J, Bessler WG. Murine bone marrow-derived macrophages constitute feeder cells for human B cell hybridomas. J Immunol Methods. 1996;196:85–91. doi: 10.1016/0022-1759(96)00121-4. [DOI] [PubMed] [Google Scholar]
  96. Hollinger FB, Liang TJ. Hepatitis B virus. In: Knipe DM, Howley PM, editors. Fields virology. Philadelphia: Lippincott Williams and Wilkins; 2001. pp. 2971–3036. [Google Scholar]
  97. Holt SE, Glinsky VV, Ivanova AB, Glinsky GV. Resistance to apoptosis in human cells conferred by telomerase function and telomere stability. Mol Carcinog. 1999;25:241–248. doi: 10.1002/(SICI)1098-2744(199908)25:4<241::AID-MC2>3.0.CO;2-9. [DOI] [PubMed] [Google Scholar]
  98. Hooper JW, Custer DM, Thompson E. Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates. Virology. 2003;306:181–195. doi: 10.1016/S0042-6822(02)00038-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  99. Ichimori Y, Sasano K, Itoh H, Hitotsumachi S, Kimura Y, Kaneko K, Kida M, Tsukamoto K. Establishment of hybridomas secreting human monoclonal antibodies against tetanus toxin and hepatitis B virus surface antigen. Biochem Biophys Res Commun. 1985;129:26–33. doi: 10.1016/0006-291X(85)91397-X. [DOI] [PubMed] [Google Scholar]
  100. Ichimori Y, Harada K, Hitotsumachi S, Tsukamoto K. Establishment of hybridoma secreting human monoclonal antibody against hepatitis B virus surface antigen. Biochem Biophys Res Commun. 1987;142:805–812. doi: 10.1016/0006-291X(87)91485-9. [DOI] [PubMed] [Google Scholar]
  101. Ip HM, Lelie PN, Wong VC, Kuhns MC, Reesink HW. Prevention of hepatitis B virus carrier state in infants according to maternal serum levels of HBV DNA. Lancet. 1989;1:406–410. doi: 10.1016/S0140-6736(89)90003-2. [DOI] [PubMed] [Google Scholar]
  102. Jessup CF, Baxendale H, Goldblatt D, Zola H. Preparation of human-mouse heterohybridomas against an immunising antigen. J Immunol Methods. 2000;246:187–202. doi: 10.1016/S0022-1759(00)00293-3. [DOI] [PubMed] [Google Scholar]
  103. Kabir A, Alavian SM, Ahanchi N, Malekzadeh R. Combined passive and active immunoprophylaxis for preventing perinatal transmission of the hepatitis B virus in infants born to HBsAg positive mothers in comparison with vaccine alone. Hepatol Res. 2006;36:265–271. doi: 10.1016/j.hepres.2006.08.001. [DOI] [PubMed] [Google Scholar]
  104. Kalantarov GF, Rudchenko SA, Lobel L, Trakht I. Development of a fusion partner cell line for efficient production of human monoclonal antibodies from peripheral blood lymphocytes. Hum Antibodies. 2002;11:85–96. [PubMed] [Google Scholar]
  105. Kang AS, Jones TM, Burton DR. Antibody redesign by chain shuffling from random combinatorial immunoglobulin libraries. Proc Natl Acad Sci U S A. 1991;88:11120–11123. doi: 10.1073/pnas.88.24.11120. [DOI] [PMC free article] [PubMed] [Google Scholar]
  106. Kanzaki Y, Onoue F, Sakurai H, Ide T. Telomerase upregulates expression levels of interleukin (IL)-1alpha, IL-1beta, IL-6, IL-8, and granulocyte-macrophage colony-stimulating factor in normal human fibroblasts. Biochem Biophys Res Commun. 2003;305:150–154. doi: 10.1016/S0006-291X(03)00717-4. [DOI] [PubMed] [Google Scholar]
  107. Karpas A, Dremucheva A, Czepulkowski BH. A human myeloma cell line suitable for the generation of human monoclonal antibodies. Proc Natl Acad Sci U S A. 2001;98:1799–1804. doi: 10.1073/pnas.98.4.1799. [DOI] [PMC free article] [PubMed] [Google Scholar]
  108. Keller MA, Stiehm ER. Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev. 2000;13:602–614. doi: 10.1128/CMR.13.4.602-614.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  109. Kirman I, Kalantarov GF, Lobel LI, Hibshoosh H, Estabrook A, Canfield R, Trakht I. Isolation of native human monoclonal autoantibodies to breast cancer. Hybrid Hybridomics. 2002;21:405–414. doi: 10.1089/153685902321043936. [DOI] [PubMed] [Google Scholar]
  110. Kitamura K, Yamada K, Kuzushima K, Morishima T, Morishima Y, Yamamoto N, Nishiyama Y, Ohya K, Yamaguchi H. Human monoclonal antibodies to human cytomegalovirus derived from peripheral blood lymphocytes of healthy adults. J Med Virol. 1990;32:60–66. doi: 10.1002/jmv.1890320111. [DOI] [PubMed] [Google Scholar]
  111. Kocher AA, Bonaros N, Dunkler D, Ehrlich M, Schlechta B, Zweytick B, Grimm M, Zuckermann A, Wolner E, Laufer G. Long-term results of CMV hyperimmune globulin prophylaxis in 377 heart transplant recipients. J Heart Lung Transplant. 2003;22:250–257. doi: 10.1016/S1053-2498(02)00474-6. [DOI] [PubMed] [Google Scholar]
  112. Koropatnick J, Pearson J, Harris JF. Extensive loss of human DNA accompanies loss of antibody production in heteromyeloma hybridoma cells. Mol Biol Med. 1988;5:69–83. [PubMed] [Google Scholar]
  113. Kozbor D, Roder JC, Chang TH, Steplewski Z, Koprowski H. Human anti-tetanus toxoid monoclonal antibody secreted by EBV-transformed human B cells fused with murine myeloma. Hybridoma. 1982;1:323–328. doi: 10.1089/hyb.1.1982.1.323. [DOI] [PubMed] [Google Scholar]
  114. Kozbor D, Roder JC, Sierzega ME, Cole SP, Croce CM. Comparative phenotypic analysis of available human hybridoma fusion partners. Methods Enzymol. 1986;121:120–140. doi: 10.1016/0076-6879(86)21013-7. [DOI] [PubMed] [Google Scholar]
  115. Krause I, Wu R, Sherer Y, Patanik M, Peter JB, Shoenfeld Y. In vitro antiviral and antibacterial activity of commercial intravenous immunoglobulin preparations—a potential role for adjuvant intravenous immunoglobulin therapy in infectious diseases. Transfus Med. 2002;12:133–139. doi: 10.1046/j.1365-3148.2002.00360.x. [DOI] [PubMed] [Google Scholar]
  116. Krenn V, von Landenberg P, Wozniak E, Kissler C, Hermelink HK, Zimmermann U, Vollmers HP. Efficient immortalization of rheumatoid synovial tissue B-lymphocytes. A comparison between the techniques of electric field-induced and PEG fusion. Hum Antibodies Hybridomas. 1995;6:47–51. [PubMed] [Google Scholar]
  117. Lafon M, Edelman L, Bouvet JP, Lafage M, Montchatre E. Human monoclonal antibodies specific for the rabies virus glycoprotein and N protein. J Gen Virol. 1990;71:1689–1696. doi: 10.1099/0022-1317-71-8-1689. [DOI] [PubMed] [Google Scholar]
  118. Lane JM, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968. N Engl J Med. 1969;281:1201–1208. doi: 10.1056/NEJM196911272812201. [DOI] [PubMed] [Google Scholar]
  119. Lanzavecchia A, Bernasconi N, Traggiai E, Ruprecht CR, Corti D, Sallusto F. Understanding and making use of human memory B cells. Immunol Rev. 2006;211:303–309. doi: 10.1111/j.0105-2896.2006.00403.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  120. Larrick JW, Truitt KE, Raubitschek AA, Senyk G, Wang JC. Characterization of human hybridomas secreting antibody to tetanus toxoid. Proc Natl Acad Sci U S A. 1983;80:6376–6380. doi: 10.1073/pnas.80.20.6376. [DOI] [PMC free article] [PubMed] [Google Scholar]
  121. Law M, Smith GL. Antibody neutralization of the extracellular enveloped form of vaccinia virus. Virology. 2001;280:132–142. doi: 10.1006/viro.2000.0750. [DOI] [PubMed] [Google Scholar]
  122. Lewis AP, Lemon SM, Barber KA, Murphy P, Parry NR, Peakman TC, Sims MJ, Worden J, Crowe JS. Rescue, expression, and analysis of a neutralizing human anti-hepatitis A virus monoclonal antibody. J Immunol. 1993;151:2829–2838. [PubMed] [Google Scholar]
  123. Lewis FM, Chernak E, Goldman E, Li Y, Karem K, Damon IK, Henkel R, Newbern EC, Ross P, Johnson CC. Ocular vaccinia infection in laboratory worker, Philadelphia, 2004. Emerg Infect Dis. 2006;12:134–137. doi: 10.3201/eid1201.051126. [DOI] [PMC free article] [PubMed] [Google Scholar]
  124. Lo KJ, Tsai YT, Lee SD, Wu TC, Wang JY, Chen GH, Yeh CL, Chiang BN, Yeh SH, Goudeau A, et al. Immunoprophylaxis of infection with hepatitis B virus in infants born to hepatitis B surface antigen-positive carrier mothers. J Infect Dis. 1985;152:817–822. doi: 10.1093/infdis/152.4.817. [DOI] [PubMed] [Google Scholar]
  125. Love JC, Ronan JL, Grotenbreg GM, van der Veen AG, Ploegh HL. A microengraving method for rapid selection of single cells producing antigen-specific antibodies. Nat Biotechnol. 2006;24:703–707. doi: 10.1038/nbt1210. [DOI] [PubMed] [Google Scholar]
  126. Meijer PJ, Andersen PS, Haahr Hansen M, Steinaa L, Jensen A, Lantto J, Oleksiewicz MB, Tengbjerg K, Poulsen TR, Coljee VW, Bregenholt S, Haurum JS, Nielsen LS. Isolation of human antibody repertoires with preservation of the natural heavy and light chain pairing. J Mol Biol. 2006;358:764–772. doi: 10.1016/j.jmb.2006.02.040. [DOI] [PubMed] [Google Scholar]
  127. Moudgil A, Shidban H, Nast CC, Bagga A, Aswad S, Graham SL, Mendez R, Jordan SC. Parvovirus B19 infection-related complications in renal transplant recipients: treatment with intravenous immunoglobulin. Transplantation. 1997;64:1847–1850. doi: 10.1097/00007890-199712270-00037. [DOI] [PubMed] [Google Scholar]
  128. Ohizumi Y, Suzuki H, Matsumoto Y, Masuho Y, Numazaki Y. Neutralizing mechanisms of two human monoclonal antibodies against human cytomegalovirus glycoprotein 130/55. J Gen Virol. 1992;73:2705–2707. doi: 10.1099/0022-1317-73-10-2705. [DOI] [PubMed] [Google Scholar]
  129. Ohlin M, Borrebaeck CA. Characteristics of human antibody repertoires following active immune responses in vivo. Mol Immunol. 1996;33:583–592. doi: 10.1016/0161-5890(96)00018-1. [DOI] [PubMed] [Google Scholar]
  130. Ohlin M, Sundqvist VA, Mach M, Wahren B, Borrebaeck CA. Fine specificity of the human immune response to the major neutralization epitopes expressed on cytomegalovirus gp58/116 (gB), as determined with human monoclonal antibodies. J Virol. 1993;67:703–710. doi: 10.1128/jvi.67.2.703-710.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  131. Olsson L, Kronstrom H, Cambon-De Mouzon A, Honsik C, Brodin T, Jakobsen B. Antibody producing human-human hybridomas. I. Technical aspects. J Immunol Methods. 1983;61:17–32. doi: 10.1016/0022-1759(83)90004-2. [DOI] [PubMed] [Google Scholar]
  132. Oral HB, Ozakin C, Akdis CA. Back to the future: antibody-based strategies for the treatment of infectious diseases. Mol Biotechnol. 2002;21:225–239. doi: 10.1385/MB:21:3:225. [DOI] [PubMed] [Google Scholar]
  133. Oshimura M, Barrett JC. Multiple pathways to cellular senescence: role of telomerase repressors. Eur J Cancer. 1997;33:710–715. doi: 10.1016/S0959-8049(97)00090-7. [DOI] [PubMed] [Google Scholar]
  134. Panova I, Gustafsson B. Increased human hybridoma formation by electrofusion of human B cells with heteromyeloma SPAM-8 cells. Hybridoma. 1995;14:265–269. doi: 10.1089/hyb.1995.14.265. [DOI] [PubMed] [Google Scholar]
  135. Pavoni E, Monteriu G, Cianfriglia M, Minenkova O. New display vector reduces biological bias for expression of antibodies in E. coli. Gene. 2006;391:120–129. doi: 10.1016/j.gene.2006.12.009. [DOI] [PubMed] [Google Scholar]
  136. Pereira-Smith OM, Robetorye S, Ning Y, Orson FM. Hybrids from fusion of normal human T lymphocytes with immortal human cells exhibit limited life span. J Cell Physiol. 1990;144:546–549. doi: 10.1002/jcp.1041440324. [DOI] [PubMed] [Google Scholar]
  137. Perkins S, Zimmermann U, Foung SK. Parameters to enhance human hybridoma formation with hypoosmolar electrofusion. Hum Antibodies Hybridomas. 1991;2:155–159. [PubMed] [Google Scholar]
  138. Posner MR, Elboim H, Santos D. The construction and use of a human-mouse myeloma analogue suitable for the routine production of hybridomas secreting human monoclonal antibodies. Hybridoma. 1987;6:611–625. doi: 10.1089/hyb.1987.6.611. [DOI] [PubMed] [Google Scholar]
  139. Potera C (2005) Filling the niche for effective MAb screening. Genet Eng News 25
  140. Pratt M, Mikhalev A, Glassy MC. The generation of Ig-secreting UC 729–6 derived human hybridomas by electrofusion. Hybridoma. 1987;6:469–477. doi: 10.1089/hyb.1987.6.469. [DOI] [PubMed] [Google Scholar]
  141. Ramirez JC, Tapia E, Esteban M. Administration to mice of a monoclonal antibody that neutralizes the intracellular mature virus form of vaccinia virus limits virus replication efficiently under prophylactic and therapeutic conditions. J Gen Virol. 2002;83:1059–1067. doi: 10.1099/0022-1317-83-5-1059. [DOI] [PubMed] [Google Scholar]
  142. Redfield RR, Wright DC, James WD, Jones TS, Brown C, Burke DS. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N Engl J Med. 1987;316:673–676. doi: 10.1056/NEJM198703123161106. [DOI] [PubMed] [Google Scholar]
  143. Redmond MJ, Leyritz-Wills M, Winger L, Scraba DG. The selection and characterization of human monoclonal antibodies to human cytomegalovirus. J Virol Methods. 1986;14:9–24. doi: 10.1016/0166-0934(86)90003-0. [DOI] [PubMed] [Google Scholar]
  144. Rioux JD, Larose Y, Brodeur BR, Radzioch D, Newkirk MM. Structural characteristics of four human hybridoma antibodies specific for the pp65 protein of the human cytomegalovirus and their relationship to human rheumatoid factors. Mol Immunol. 1994;31:585–597. doi: 10.1016/0161-5890(94)90166-X. [DOI] [PubMed] [Google Scholar]
  145. Rodriguez WJ, Gruber WC, Welliver RC, Groothuis JR, Simoes EA, Meissner HC, Hemming VG, Hall CB, Lepow ML, Rosas AJ, Robertsen C, Kramer AA. Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study Group. Pediatrics. 1997;99:454–461. doi: 10.1542/peds.99.3.454. [DOI] [PubMed] [Google Scholar]
  146. Ruttmann E, Geltner C, Bucher B, Ulmer H, Hofer D, Hangler HB, Semsroth S, Margreiter R, Laufer G, Muller LC. Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation. Transplantation. 2006;81:1415–1420. doi: 10.1097/01.tp.0000209439.27719.ed. [DOI] [PubMed] [Google Scholar]
  147. Sa’adu A, Locniskar M, Bidwell D, Howard C, McAdam KP, Voller A. Development and characterization of human anti-HBs antibodies. J Virol Methods. 1992;36:25–34. doi: 10.1016/0166-0934(92)90154-6. [DOI] [PubMed] [Google Scholar]
  148. Saphire EO, Parren PW, Pantophlet R, Zwick MB, Morris GM, Rudd PM, Dwek RA, Stanfield RL, Burton DR, Wilson IA. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science. 2001;293:1155–1159. doi: 10.1126/science.1061692. [DOI] [PubMed] [Google Scholar]
  149. Sawyer LA. Antibodies for the prevention and treatment of viral diseases. Antiviral Res. 2000;47:57–77. doi: 10.1016/S0166-3542(00)00111-X. [DOI] [PubMed] [Google Scholar]
  150. Schlom J, Wunderlich D, Teramoto YA. Generation of human monoclonal antibodies reactive with human mammary carcinoma cells. Proc Natl Acad Sci U S A. 1980;77:6841–6845. doi: 10.1073/pnas.77.11.6841. [DOI] [PMC free article] [PubMed] [Google Scholar]
  151. Schmidt E, Leinfelder U, Gessner P, Zillikens D, Brocker EB, Zimmermann U. CD19+ B lymphocytes are the major source of human antibody-secreting hybridomas generated by electrofusion. J Immunol Methods. 2001;255:93–102. doi: 10.1016/S0022-1759(01)00431-8. [DOI] [PubMed] [Google Scholar]
  152. Sechet A, Bridoux F, Bauwens M, Ayache RA, Belmouaz S, Touchard G. Prevention of cytomegalovirus infection and disease in high-risk renal transplant recipients with polyvalent intravenous immunoglobulins. Transplant Proc. 2002;34:812–813. doi: 10.1016/S0041-1345(01)02920-7. [DOI] [PubMed] [Google Scholar]
  153. Shay DK, Holman RC, Roosevelt GE, Clarke MJ, Anderson LJ. Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979–1997. J Infect Dis. 2001;183:16–22. doi: 10.1086/317655. [DOI] [PubMed] [Google Scholar]
  154. Shirahata S, Katakura Y, Teruya K. Cell hybridization, hybridomas, and human hybridomas. Methods Cell Biol. 1998;57:111–145. doi: 10.1016/S0091-679X(08)61575-7. [DOI] [PubMed] [Google Scholar]
  155. Shulman M, Wilde CD, Kohler G. A better cell line for making hybridomas secreting specific antibodies. Nature. 1978;276:269–270. doi: 10.1038/276269a0. [DOI] [PubMed] [Google Scholar]
  156. Siemoneit K, da Silva Cardoso M, Wolpl A, Koerner K, Subanek B. Isolation and epitope characterization of human monoclonal antibodies to hepatitis C virus core antigen. Hybridoma. 1994;13:9–13. doi: 10.1089/hyb.1994.13.9. [DOI] [PubMed] [Google Scholar]
  157. Small TN, Casson A, Malak SF, Boulad F, Kiehn TE, Stiles J, Ushay HM, Sepkowitz KA. Respiratory syncytial virus infection following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002;29:321–327. doi: 10.1038/sj.bmt.1703365. [DOI] [PubMed] [Google Scholar]
  158. Smith GL, Vanderplasschen A, Law M. The formation and function of extracellular enveloped vaccinia virus. J Gen Virol. 2002;83:2915–2931. doi: 10.1099/0022-1317-83-12-2915. [DOI] [PubMed] [Google Scholar]
  159. Smith LL, Coller HA, Roberts JM. Telomerase modulates expression of growth-controlling genes and enhances cell proliferation. Nat Cell Biol. 2003;5:474–479. doi: 10.1038/ncb985. [DOI] [PubMed] [Google Scholar]
  160. Snydman DR, Werner BG, Heinze-Lacey B, Berardi VP, Tilney NL, Kirkman RL, Milford EL, Cho SI, Bush HL, Jr, Levey AS, et al. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med. 1987;317:1049–1054. doi: 10.1056/NEJM198710223171703. [DOI] [PubMed] [Google Scholar]
  161. Sokos DR, Berger M, Lazarus HM. Intravenous immunoglobulin: appropriate indications and uses in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2002;8:117–130. doi: 10.1053/bbmt.2002.v8.pm11939601. [DOI] [PubMed] [Google Scholar]
  162. Stein LD, Sigal NH. Limiting dilution analysis of Epstein-Barr virus-induced immunoglobulin production. Cell Immunol. 1983;79:309–319. doi: 10.1016/0008-8749(83)90073-4. [DOI] [PubMed] [Google Scholar]
  163. Stewart SA, Hahn WC, O’Connor BF, Banner EN, Lundberg AS, Modha P, Mizuno H, Brooks MW, Fleming M, Zimonjic DB, Popescu NC, Weinberg RA. Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc Natl Acad Sci USA. 2002;99:12606–12611. doi: 10.1073/pnas.182407599. [DOI] [PMC free article] [PubMed] [Google Scholar]
  164. Stricker EA, Tiebout RF, Lelie PN, Zeijlemaker WP. A human monoclonal IgG1 lambda anti-hepatitis B surface antibody. Production, properties, and applications. Scand J Immunol. 1985;22:337–343. doi: 10.1111/j.1365-3083.1985.tb01889.x. [DOI] [PubMed] [Google Scholar]
  165. Sugano T, Matsumoto Y, Miyamoto C, Masuho Y. Hybridomas producing human monoclonal antibodies against varicella-zoster virus. Eur J Immunol. 1987;17:359–364. doi: 10.1002/eji.1830170309. [DOI] [PubMed] [Google Scholar]
  166. Sugano T, Tomiyama T, Matsumoto Y, Sasaki S, Kimura T, Forghani B, Masuho Y. A human monoclonal antibody against varicella-zoster virus glycoprotein III. J Gen Virol. 1991;72:2065–2073. doi: 10.1099/0022-1317-72-9-2065. [DOI] [PubMed] [Google Scholar]
  167. Tan MP, Koren G. Chickenpox in pregnancy: revisited. Reprod Toxicol. 2006;21:410–420. doi: 10.1016/j.reprotox.2005.04.011. [DOI] [PubMed] [Google Scholar]
  168. Terrault NA, Vyas G. Hepatitis B immune globulin preparations and use in liver transplantation. Clin Liver Dis. 2003;7:537–550. doi: 10.1016/S1089-3261(03)00045-X. [DOI] [PubMed] [Google Scholar]
  169. Terrault NA, Zhou S, McCory RW, Pruett TL, Lake JR, Roberts JP, Ascher NL, Wright TL. Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin. Hepatology. 1998;28:555–561. doi: 10.1002/hep.510280237. [DOI] [PubMed] [Google Scholar]
  170. Thompson JM, Lowe J, McDonald DF. Human monoclonal anti-D secreting heterohybridomas from peripheral B lymphocytes expanded in the CD40 system. J Immunol Methods. 1994;175:137–140. doi: 10.1016/0022-1759(94)90340-9. [DOI] [PubMed] [Google Scholar]
  171. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, Fukuda K. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289:179–186. doi: 10.1001/jama.289.2.179. [DOI] [PubMed] [Google Scholar]
  172. Tian C, Luskin GK, Dischert KM, Higginbotham JN, Shepherd BE, Crowe JE., Jr Evidence for preferential Ig gene usage and differential TdT and exonuclease activities in human naive and memory B cells. Mol Immunol. 2007;44:2173–2183. doi: 10.1016/j.molimm.2006.11.020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  173. Tiebout RF, van Boxtel-Oosterhof F, Stricker EA, Zeijlemaker WP. A human hybrid hybridoma. J Immunol. 1987;139:3402–3405. [PubMed] [Google Scholar]
  174. Traggiai E, Becker S, Subbarao K, Kolesnikova L, Uematsu Y, Gismondo MR, Murphy BR, Rappuoli R, Lanzavecchia A. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med. 2004;10:871–875. doi: 10.1038/nm1080. [DOI] [PMC free article] [PubMed] [Google Scholar]
  175. Ueki Y, Goldfarb IS, Harindranath N, Gore M, Koprowski H, Notkins AL, Casali P. Clonal analysis of a human antibody response. Quantitation of precursors of antibody-producing cells and generation and characterization of monoclonal IgM, IgG, and IgA to rabies virus. J Exp Med. 1990;171:19–34. doi: 10.1084/jem.171.1.19. [DOI] [PMC free article] [PubMed] [Google Scholar]
  176. Vaisbourd M, Ignatovich O, Dremucheva A, Karpas A, Winter G. Molecular characterization of human monoclonal antibodies derived from fusions of tonsil lymphocytes with a human myeloma cell line. Hybrid Hybridomics. 2001;20:287–292. doi: 10.1089/15368590152740680. [DOI] [PubMed] [Google Scholar]
  177. Varga M, Remport A, Hidvegi M, Peter A, Kobori L, Telkes G, Fazakas J, Gerlei Z, Sarvary E, Sulyok B, Jaray J. Comparing cytomegalovirus prophylaxis in renal transplantation: single center experience. Transpl Infect Dis. 2005;7:63–67. doi: 10.1111/j.1399-3062.2005.00094.x. [DOI] [PubMed] [Google Scholar]
  178. Welliver RC. Respiratory syncytial virus and other respiratory viruses. Pediatr Infect Dis J. 2003;22:S6–S10. doi: 10.1097/00006454-200302001-00002. [DOI] [PubMed] [Google Scholar]
  179. Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR. Making antibodies by phage display technology. Annu Rev Immunol. 1994;12:433–455. doi: 10.1146/annurev.iy.12.040194.002245. [DOI] [PubMed] [Google Scholar]
  180. Xiao XM, Li AZ, Chen X, Zhu YK, Miao J. Prevention of vertical hepatitis B transmission by hepatitis B immunoglobulin in the third trimester of pregnancy. Int J Gynaecol Obstet. 2007;96:167–170. doi: 10.1016/j.ijgo.2006.11.011. [DOI] [PubMed] [Google Scholar]
  181. Xu JL, Davis MM. Diversity in the CDR3 region of V(H) is sufficient for most antibody specificities. Immunity. 2000;13:37–45. doi: 10.1016/S1074-7613(00)00006-6. [DOI] [PubMed] [Google Scholar]
  182. Xu Q, Xiao L, Lu XB, Zhang YX, Cai X. A randomized controlled clinical trial: interruption of intrauterine transmission of hepatitis B virus infection with HBIG. World J Gastroenterol. 2006;12:3434–3437. doi: 10.3748/wjg.v12.i21.3434. [DOI] [PMC free article] [PubMed] [Google Scholar]
  183. Yoshinari K, Arai K, Kimura H, Matsumoto K, Yamaguchi Y. Efficient production of IgG human monoclonal antibodies by lymphocytes stimulated by lipopolysaccharide, pokeweed mitogen, and interleukin 4. In Vitro Cell Dev Biol Anim. 1996;32:372–377. doi: 10.1007/BF02722964. [DOI] [PubMed] [Google Scholar]
  184. Young J. Development of a potent respiratory syncytial virus-specific monoclonal antibody for the prevention of serious lower respiratory tract disease in infants. Respir Med. 2002;96(B):S31–35. doi: 10.1053/rmed.2002.1298. [DOI] [PubMed] [Google Scholar]
  185. Zhu Y, Jin B, Sun C, Huang C, Liu X. The effects of hybridoma growth factor in conditioned media upon the growth, cloning, and antibody production of heterohybridoma cell lines. Hum Antibodies Hybridomas. 1993;4:31–35. [PubMed] [Google Scholar]
  186. Zhu Y, Jin B, Jiang S, Sun K, Sun C, Liu X. Improved fusion partners transfected with DNA fragment encoding IL-11 on generation of human B lymphocyte hybridomas. Hum Antibodies. 1999;9:1–7. [PubMed] [Google Scholar]
  187. Zikos P, Van Lint MT, Lamparelli T, Gualandi F, Occhini D, Mordini N, Berisso G, Bregante S, Bacigalupo A. A randomized trial of high dose polyvalent intravenous immunoglobulin (HDIgG) vs. Cytomegalovirus (CMV) hyperimmune IgG in allogeneic hemopoietic stem cell transplants (HSCT) Haematologica. 1998;83:132–137. [PubMed] [Google Scholar]

Articles from Human Antibody Therapeutics for Viral Disease are provided here courtesy of Nature Publishing Group

RESOURCES